drugset / Trial / NCT05258331
Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of CT303 in Patients With Psoriasis
NaSingle-groupOpen-labelTreatment
Summary
Investigate the Safety, Tolerability, Efficacy and pharmacodynamics properties of CT303 in patients with moderate to severe plaque psoriasis
Timeline
- Start
- 2021-10-25
- Primary completion
- 2024-08-30
- Completion
- 2024-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CT303 | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | CT303 | Cell therapy | 2e+06 cells/kg | Intravenous |
| Subject | CT303 | Cell therapy | 3e+06 cells/kg | Intravenous |